Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01280695 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Metabolic Solutions Development Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 14
- Study locations
NCT01280695 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Metabolic Solutions Development Company. The registered enrollment target is 129 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT01280695, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Metabolic Solutions Development Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG MSDC-0602 100 mg
- DRUG MSDC-0602 250 mg
Study Locations (14)
Florida
- - Bradenton
- - Hialeah
- - Pembroke Pines
California
- - Chula Vista
- - Los Angeles
Texas
- - Austin
- - San Antonio
Arizona
- - Goodyear
Illinois
- - Chicago
Montana
- - Butte
North Carolina
- - Greensboro
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01280695
The ClinicalTrials.gov registry entry for NCT01280695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The listed sponsor is Metabolic Solutions Development Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01280695 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT01280695 about?
NCT01280695 is a clinical study titled "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients". The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
What is the current status of trial NCT01280695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2011-02. Estimated completion is 2011-06.
What conditions does trial NCT01280695 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01280695?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), MSDC-0602 100 mg (DRUG), MSDC-0602 250 mg (DRUG).
Who is sponsoring clinical trial NCT01280695?
This trial is sponsored by Metabolic Solutions Development Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01280695 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Illinois, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.